A Retrospective Analysis of a Commercially Available Platelet‐Rich Plasma Kit During Clinical Use

A Comparison of the in Vitro and in Vivo Thrombogenic Activity of Factor IX Concentrates Using Stasis (Wessler) and Non-Stasis Rabbit Models

Thrombosis and Haemostasis ◽

10.1055/s-0038-1650089 ◽

1980 ◽

Vol 44 (02) ◽

pp. 081-086 ◽

Cited By ~ 8

Author(s):

C V Prowse ◽

A E Williams

Keyword(s):

Platelet Rich Plasma ◽

Thrombus Formation ◽

Factor Ix ◽

Coagulation System ◽

In Vitro Tests ◽

Clinical Use ◽

Low Activity

SummaryThe thrombogenic effects of selected factor IX concentrates were evaluated in two rabbit models; the Wessler stasis model and a novel non-stasis model. Concentrates active in either the NAPTT or TGt50 in vitro tests of potential thrombogenicity, or both, caused thrombus formation in the Wessler technique and activation of the coagulation system in the non-stasis model. A concentrate with low activity in both in vitro tests did not have thrombogenic effects in vivo, at the chosen dose. Results in the non-stasis model suggested that the thrombogenic effects of factor IX concentrates may occur by at least two mechanisms. A concentrate prepared from platelet-rich plasma and a pyrogenic concentrate were also tested and found to have no thrombogenic effect in vivo.These studies justify the use of the NAPTT and TGt50 in vitro tests for the screening of factor IX concentrates prior to clinical use.

Download Full-text

Hollow Fiber Oxygenator Composition Has a Significant Impact on Failure Rates in Neonates on Extracorporeal Membrane Oxygenation: A Retrospective Analysis

Journal of Pediatric Intensive Care ◽

10.1055/s-0037-1599150 ◽

2017 ◽

Vol 07 (01) ◽

pp. 007-013 ◽

Cited By ~ 4

Author(s):

Philip Bernard ◽

Sean Skinner ◽

Prasad Bhandary ◽

Ana Ruzic ◽

Matthew Bacon ◽

...

Keyword(s):

Retrospective Study ◽

Extracorporeal Membrane Oxygenation ◽

Retrospective Analysis ◽

Hollow Fiber ◽

Life Support ◽

Extracorporeal Life Support ◽

Clinical Use ◽

Failure Rates ◽

Membrane Oxygenation

AbstractIn extracorporeal life support (ECLS), there are two main types of oxygenators in clinical use for neonates: polymethylpentene (PMP) hollow fiber and polypropylene (PP) hollow fiber. A retrospective study was performed on neonates (n = 44) who had undergone ECLS for noncardiac indications from 2009 to 2015. Between the two groups (PMP n = 21, PP n = 23), the PP oxygenators failed 91% of the time, whereas the PMP oxygenators failed 43% of the time (p < 0.05). Analysis suggests PMP oxygenators are less prone to failure than PP oxygenators, and they require fewer number of oxygenator changes during a neonatal ECLS.

Download Full-text

A Retrospective Analysis of Clinical Use and Outcomes Using Viable Placental Membrane Allografts in Chronic Wounds

WOUNDS A Compendium of Clinical Research and Practice ◽

10.25270/wnds/2021.329333 ◽

2021 ◽

Vol 33 (12) ◽

pp. 329-333

Author(s):

Laura Swoboda

Keyword(s):

Retrospective Analysis ◽

Real World ◽

Chronic Wounds ◽

Chronic Wound ◽

Arterial Disease ◽

Wound Management ◽

Foot Ulcers ◽

Controlled Trials ◽

Clinical Use ◽

Exposed Bone

Introduction. Viable placental membrane (vPM) has been shown to decrease time to healing, adverse wound events, and wound-related infections. Wound research exclusion criteria commonly exclude wound types other than diabetic foot ulcers and venous leg ulcers (VLUs), comorbidities including peripheral arterial disease (PAD) and uncontrolled diabetes mellitus (DM), and wounds with exposed bone or tendon. Objective. This retrospective research study evaluated the clinical use and outcomes of the vPM with living mesenchymal stem cells used in chronic wound management in the community hospital outpatient department setting with the goal of comparing real-world use and outcomes of the product with use and outcomes described in the chronic wound literature. Materials and Methods. A retrospective analysis on vPM treatments at a Wisconsin academic health system’s community hospitals. Participants included all patients who received vPM therapy between July 1, 2016, and August 21, 2019. Results. A total of 89 patients received vPM treatment during the study period (mean age, 70 years; 69% male [n = 61], 31% female [n = 28]). Wound types were 54% diabetic or neuropathic foot ulcers (n = 48), 17% VLUs (n = 15), 7% pressure injuries (n = 6), and 22% atypical wounds (n = 20). The average wound duration prior to vPM initiation was 104 days. Average wound size at presentation was 6.9 cm2. Of study participants 54% had PAD (n = 48), 63% had DM (n = 56), 33.7% had DM and PAD (n = 30), and 17% had exposed bone or tendon (n = 15). Average adjusted time to healing after initiation of vPM was 81.2 days. The percentage of wounds healed 12 weeks after initiation of vPM treatment was 57%. Conclusions. Effectiveness of vPM observed in controlled trials also was observed in this real-world study on vPM for multiple wound types, patients with comorbidities including PAD and uncontrolled DM, and wounds with exposed bone or tendon. Results of this study were not statistically different from those reported in the literature. More randomized controlled trials are needed to explore the efficacy of vPM on patient presentations common to wound healing centers.

Download Full-text

Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results

Advances in Therapy ◽

10.1007/s12325-020-01308-y ◽

2020 ◽

Vol 37 (5) ◽

pp. 2390-2412 ◽

Cited By ~ 3

Author(s):

Umut Arslan ◽

Emin Özmert

Keyword(s):

Retinitis Pigmentosa ◽

Retrospective Analysis ◽

Platelet Rich Plasma ◽

Electromagnetic Stimulation

Download Full-text

Indium (111In)-Labelled Human Platelets: Optimal Method

Clinical Science ◽

10.1042/cs0580243 ◽

1980 ◽

Vol 58 (3) ◽

pp. 243-248 ◽

Cited By ~ 90

Author(s):

R. J. Hawker ◽

Linda M. Hawker ◽

A. R. Wilkinson

Keyword(s):

Healthy Volunteer ◽

Survival Time ◽

Platelet Rich Plasma ◽

Adenosine Diphosphate ◽

Human Platelets ◽

Laboratory Method ◽

Clinical Use ◽

Optimal Method ◽

Normal Platelet

1. A detailed laboratory method is described for the labelling of human platelets with [111In]indium oxine. The 45 min method is simple, requires only 26 ml of blood and is suitable for routine clinical use. 2. After the labelling and resuspension of the platelets in plasma, aggregation responses to both adenosine diphosphate and collagen were similar to those of normal platelet-rich plasma. Less than 5% of the [111In]indium oxine was released by secretory functions of platelets. 3. Labelling efficiencies of 90·1 ± 4·29% (n = 28) were achieved in 60 s by normal concentrations of plasma-free platelet suspensions. 4. Platelet survival in vivo in healthy volunteer subjects follows a linear function with a survival time of 8·44 ± 0·18 days.

Download Full-text

Building and Clinical Use of Activated Plasma Clotting Time Test and the Value of APCT on Predicting the Bleeding Due to Leukemia Chemotherapy-Induced Thrombocytopenia.

Blood ◽

10.1182/blood.v110.11.3915.3915 ◽

2007 ◽

Vol 110 (11) ◽

pp. 3915-3915

Author(s):

Bao-An Chen ◽

Jin-Jin Li ◽

Cheng-Yin Huang ◽

Feng Gao ◽

Jian Chen ◽

...

Keyword(s):

Sodium Citrate ◽

Platelet Rich Plasma ◽

Venous Blood ◽

Clinical Use ◽

Clotting Time ◽

Platelet Suspension ◽

Platelet Poor Plasma ◽

Platelet Counts ◽

Significant Difference ◽

Time Test

Abstract Objective This study was aimed to determine the optimal concertration of C-PG in activated plasma clotting time (APCT) test and build the APCT test.To investigate the value of activated plasma clotting time test (APCT) on predicting the bleeding due to Leukemia chemotherapy-induced thrombocytopenia. Method We collected healthy blood donors’venous blood, prepared watched platelet suspension and platelet rich plasma in a normal way to which we add different concertrations of C-PG, then test expression of AnnexinV in the surface of activated platelet by FCM. Prepared platelet rich plasma and platelet poor plasma in a normal way to which we add different concertrations of C-PG, then count the plasma clotting time.Forty-one patients with leukemia chemotherapy, twenty-one patients with petechiae or epistaxis or gum bleeding and twenty patients without bleeding symptoms, were involved in the test. Drawed their venous blood and collected in 3.2% buffered sodium citrate(9:1), the platelet counts and APCT, PT, APTT, TT, Fig were assesed. Result Bleeding group’s APCT was obviously prolonged contrast to the non-bleeding group’s. Platelet counts and APCT of the bleeding group and the non-bleeding group were (7.2±2.9) ×109/L, (105.9±8.1)s and (23.0±12.2) ×109/L,(71.4±9.0)s respectively. There was significant difference between the two groups (P<0.01). Using APCT≥90s as the cut-off point to predict the bleeding caused by chemotherapy-induced thrombocytopenia, the sensibility was 100%, and the specificity was 95.7%. Using platelet counts ≤15*109/L, the sensibility and the specificity was 95.2% and 69.0%. PT, APTT, TT, Fig of the bleeding group and the non-bleeding group were 11.7±1.1)S,(31.5±1.3)S,(11.1±1.2)S,(2.37±0.41)g/L and (12.1±0.8)S,(30.8±2.1)S,(10.7±0.9)S,(2.64±0.27)g/L respectively. The results of the two groups were all not significantly different (P>0.05). Conclusion APCT is a good indication of predicting the bleeding due to leukemia chemotherapy -induced thrombocytopenia.

Download Full-text